Anavex Life Sciences (AVXL) 25th Annual Needham Virtual Healthcare Conference summary

Strategic focus and pipeline overview

• Emphasis on developing oral medicines for brain health, targeting Alzheimer's, Parkinson's, and rare diseases like Rett syndrome and Fragile X.

• Blarcamesine, the lead candidate, showed significant slowing of Alzheimer's progression in phase IIb/III trials, with strong safety and no neuroimaging adverse events.

• Pipeline includes additional oral and liquid formulations for pediatric and rare indications, and ANAVEX 3-71 for schizophrenia.

• Platform approach targets autophagy impairment and cellular stress, aiming for broad CNS disorder coverage.

• Financially stable with over $130 million in cash, no debt, and funding secured for over three years.

Clinical results and mechanism of action

• Blarcamesine demonstrated a 36% slowing in clinical progression (ADAS-Cog-13) over 48 weeks, with up to 50% in a pre-specified population.

• Biomarker improvements included reduced brain atrophy and significant changes in plasma Aβ42/40 ratio.

• Mechanism involves restoring autophagy via sigma-1 receptor and GABARAP, impacting key neurodegenerative pathways.

• Long-term extension study showed sustained cognitive benefit, with 17.8 months of preserved function and no deaths.

• Precision medicine cohort (ABCLEAR-3) showed nearly no decline over 48 weeks, approximating normal aging.

Regulatory and development plans

• Engaged in ongoing discussions with regulatory agencies (EMA, FDA) to define pivotal study pathways for market authorization.

• Next pivotal studies for Alzheimer's will use CDR Sum of Boxes as the primary endpoint over 18 months.

• Site engagement and protocol optimization underway, with strong interest due to oral administration and broad inclusion criteria.

• Similar regulatory strategies being applied to Parkinson's and Rett syndrome, leveraging EMA review learnings.